

Product Name: BET bromodomain inhibitor
Revision Date: 01/10/2021

# **Product Data Sheet**

# **BET** bromodomain inhibitor

**Cat. No.:** B5887


CAS No.: 1380087-89-7
Formula: C20H16CIN3O2

M.Wt: 365.81

**Synonyms:** CPI-0610; CPI0610; CPI 0610

Target: Chromatin/Epigenetics

Pathway: Bromodomain
Storage: Store at -20°C



# **Solvent & Solubility**

insoluble in H2O; insoluble in EtOH; ≥18.3 mg/mL in DMSO

In Vitro

Preparing Stock Solutions	Solvent  Concentration	1mg	5mg	10mg
	1 mM	2.7337 mL	13.6683 mL	27.3366 mL
	5 mM	0.5467 mL	2.7337 mL	5.4673 mL
	10 mM	0.2734 mL	1.3668 mL	2.7337 mL

Please refer to the solubility information to select the appropriate solvent.

# **Biological Activity**

Reacting conditions:

Shortsummary	Potent and selective inhibitor for BRD4		
IC <sub>50</sub> & Target			
	Cell Viability Assay	Control of the Contro	
	Cell Line:	Primary Multiple Myeloma cell lines	
	Preparation method:	The solubility of this compound in DMSO is >18.3mg/mL. General tips for	
In Vitro		obtaining a higher concentration: Please warm the tube at 37°C for 10 minutes	
		and/or shake it in the ultrasonic bath for a while. Stock solution can be stored	
		below -20°C for several months.	

2 µM at 72 h

	Applications:	CPI-0610 treatment resulted in 40% decrease in viability in primary cells isolated from a newly diagnosed patient and caused 50% cell death in primary cells isolated from a relapsed disease patient.			
	Animal experiment				
In Vivo	Animal models:	Multiple Myeloma xenograft CB17-SCID mouse model			
	Dosage form:	subcutaneous injections, 10 mg/kg, twice a day for 38 days			
	Applications:	Mice treated with CPI-0610 showed a significant delay in tumor growth, and the median overall survival of CPI-0610 treated animals was significantly prolonged.			
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.			

### **Product Citations**

1. Kim SR, Lewis JM, et al. "BET inhibition in advanced cutaneous T cell lymphoma is synergistically potentiated by BCL2 inhibition or HDAC inhibition." Oncotarget. 2018 Jun 26;9(49):29193-29207.PMID:30018745

See more customer validations on www.apexbt.com.

### References

[1] Siu KT, Ramachandran J, Yee AJ, et al. Preclinical activity of CPI-0610, a novel small-molecule bromodomain and extra-terminal protein inhibitor in the therapy of multiple myeloma. Leukemia. 2017 Jan 3.

### Caution

#### FOR RESEARCH PURPOSES ONLY.

#### NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.



### **APExBIO Technology**

#### www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054. Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

APENEIO.

APENBIO.

APE BIO

APE BIO

APE BIO

APE BIO

APE, BIO

APE BIO